Trials / Completed
CompletedNCT00864279
A Relative Bioavailability Study of Cetirizine HCl 10 mg Tablets Under Fasting Conditions
Single Dose Two-Way Crossover Fasted Bioequivalence Study of Cetirizine Hydrochloride 10 mg Tablets in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- Actavis Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
To determine the pharmacokinetics and bioequivalence of cetirizine hydrochloride formulations after administration of single doses to normal healthy subjects under fasted conditions. These data were to be evaluated statistically to determine if the products meet bioequivalence criteria.
Detailed description
Study Type: Interventional Study Design: Single-dose two-way, crossover bioequivalence study with an adequate washout period (7 days) between the two periods of the study and with an equal number of subjects randomly assigned to receive the study test (Treatment A) and study reference (Treatment B). Official Title: Single Dose Two-Way Crossover Fasted Bioequivalence Study of Cetirizine Hydrochloride 10 mg Tablets in Healthy Volunteers Further study details as provided by Actavis Elizabeth LLC: Primary Outcome Measures: Rate and Extend of Absorption
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cetirizine Hydrochloride 10 mg tablets, single dose | A: Experimental Subjects received Shasun Chemicals and Drugs Ltd. formulated products under fast conditions |
| DRUG | Zyrtec® 10 mg tablets, single dose | B: Active comparator Subjects received Pfizer Inc. formulated products under fast conditions |
Timeline
- Start date
- 2006-08-01
- Primary completion
- 2006-09-01
- Completion
- 2006-09-01
- First posted
- 2009-03-18
- Last updated
- 2010-08-16
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00864279. Inclusion in this directory is not an endorsement.